Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MaxCyte ( (MXCT) ) just unveiled an announcement.
On June 25, 2025, MaxCyte, Inc. announced its decision to cancel the trading of its common stock on the AIM market of the London Stock Exchange, effective June 26, 2025. This move will not affect the company’s shares listed on the Nasdaq Global Select Market, where they will continue to trade under the ticker symbol MXCT.
The most recent analyst rating on (MXCT) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on MaxCyte stock, see the MXCT Stock Forecast page.
Spark’s Take on MXCT Stock
According to Spark, TipRanks’ AI Analyst, MXCT is a Neutral.
MaxCyte faces significant financial and technical challenges, with declining revenues and bearish technical indicators. The company’s valuation is also concerning due to negative earnings. However, strategic corporate events and some operational strengths provide a modest positive outlook.
To see Spark’s full report on MXCT stock, click here.
More about MaxCyte
Average Trading Volume: 888,614
Technical Sentiment Signal: Sell
Current Market Cap: $230.7M
For detailed information about MXCT stock, go to TipRanks’ Stock Analysis page.